Literature DB >> 8674263

Cost-effective management of heart failure.

W W Parmley1.   

Abstract

Heart failure affects more than 2 million Americans, and about 400,000 new cases are diagnosed each year. The direct economic cost is over $10 billion/year. About 75% of this cost is spent on hospitalization, and almost 20% on nursing home care. Drugs such as angiotensin-converting enzyme (ACE) inhibitors reduce mortality and hospitalization and are thus very cost effective in the management of heart failure. Cost-effective strategies should focus on keeping patients out of the hospital. Additional savings can be obtained by more appropriate utilization of tests.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8674263     DOI: 10.1002/clc.4960190319

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  9 in total

Review 1.  Outpatient management of congestive heart failure.

Authors:  E K Massin
Journal:  Tex Heart Inst J       Date:  1998

2.  Relationship between hospital length of stay and quality of care in patients with congestive heart failure.

Authors:  M P Kossovsky; F P Sarasin; P Chopard; M Louis-Simonet; P Sigaud; T V Perneger; J M Gaspoz
Journal:  Qual Saf Health Care       Date:  2002-09

Review 3.  Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies.

Authors:  Emile Levy; Pierre Levy
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 4.  Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.

Authors:  F Andersson; C Cline; T Rydén-Bergsten; L Erhardt
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 5.  Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients?

Authors:  F D Hobbs
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

6.  Clenbuterol plus granulocyte colony-stimulating factor regulates stem/progenitor cell mobilization and exerts beneficial effect by increasing neovascularization in rats with heart failure.

Authors:  Toshikazu D Tanaka; Jordan J Lancaster; Elizabeth Juneman; Joseph J Bahl; Steven Goldman
Journal:  J Card Fail       Date:  2013-07       Impact factor: 5.712

Review 7.  Myocardial revascularization as a therapeutic strategy in the patient with advanced ventricular dysfunction.

Authors:  F A Mitropoulos; J A Elefteriades
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

8.  Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure.

Authors:  T M Ramahi; M D Longo; K Rohlfs; N Sheynberg
Journal:  Clin Cardiol       Date:  2000-12       Impact factor: 2.882

9.  The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure.

Authors:  S B Liggett; L E Wagoner; L L Craft; R W Hornung; B D Hoit; T C McIntosh; R A Walsh
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.